IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity

Clostridioides difficile infection (CDI) recurs in 1 of 5 patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2+ ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Investigation
Published
2025-03-06
DOI
https://doi.org/10.1172/jci184659
Citations
4
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
5.58

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity

Farha Naz, Audrey C. Brown, Girija Ramakrishnan, Isaura Rigo et al.
4 citations
Journal of Clinical Investigation
Clostridium difficile and Clostridium perfringens research
5.58
article

IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity

Farha Naz, Audrey C. Brown, Girija Ramakrishnan, Isaura Rigo, Gregory R. Madden, William A. Petri, Rachel Boone, Mary K. Young, Md. Jashim Uddin, David Tyus, C. Fleming, Nicholas Hagspiel
article en
4 citations

Abstract

Clostridioides difficile infection (CDI) recurs in 1 of 5 patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2+ ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI.

Journal of Clinical InvestigationVol. 135(9)
Office of Infectious Diseases (US), University of Virginia (US)
National Institutes of Health
Zero hunger
Openalex Percentile: Top 5%
Clostridium difficile and Clostridium perfringens research
5.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity — Farha Naz, Audrey C. Brown, et al. · Journal of Clinical Investigation (2025) | TGRS Research Map | TGRS